The future of translational research on alcohol use disorder
Open accessThe DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
In March 2019, a scientific meeting was held at the University of California, Los Angeles (UCLA) Luskin Center to discuss approaches to expedite the translation of neurobiological insights to advances in the treatment of alcohol use disorder (AUD). A guiding theme that emerged was that while translational research in AUD is clearly a challenge, it is also a field ripe with opportunities. Herein, we seek to summarize and disseminate the recommendations for the future of translational AUD research using four sections. First, we briefly review the current landscape of AUD treatment including the available evidence‐based treatments and their uptake in clinical settings. Second, we discuss AUD treatment development efforts from a translational science viewpoint. We review current hurdles to treatment development as well as opportunities for mechanism‐informed treatment. Third, we consider models of translational science and public health impact. Together, these critical insights serve as the bases for a series of recommendations and future directions. Towards the goal of improving clinical care and population health for AUD, scientists are tasked with bolstering the clinical applicability of their research findings so as to expedite the translation of knowledge into patient care.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rehm, J., Mathers, C., Popova, S., Thavorncharoensap, M., Teerawattananon, Y., & Patra, J. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60746-7 · Cited by 3,870 · cited 1×
“Alcohol use disorder (AUD) is highly prevalent and costly to individuals and society.(1,2) It is a heterogeneous and progressive disorder,”
BackgroundNeurobiology of addiction: a neurocircuitry analysis
Koob, G. F., & Volkow, N. D. (2016) · The Lancet Psychiatry · doi:10.1016/s2215-0366(16)00104-8 · Cited by 3,698
Self-citationHasin, D. S., Stinson, F. S., Ogburn, E., & Grant, B. F. (2007) · Archives of General Psychiatry · doi:10.1001/archpsyc.64.7.830 · Cited by 2,908 · cited 1×
“cannot ignore the abysmally low rates of treatment seeking for this disorder across all age groups.(90,91) Closing the treatment gap represents a critical direction for the field and will likely engage efforts”
BackgroundGrant, B. F., Goldstein, R. B., Saha, T. D., Chou, S. P., Jung, J., Zhang, H., Pickering, R. P., Ruan, W. J., Smith, S. M., Huang, B., et al. (2015) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2015.0584 · Cited by 2,556
Grant, B. F., Chou, S. P., Saha, T. D., Pickering, R. P., Kerridge, B. T., Ruan, W. J., Huang, B., Jung, J., Zhang, H., Fan, A., et al. (2017) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2017.2161 · Cited by 1,362
The conception of the ABCD study: From substance use to a broad NIH collaboration
Volkow, N. D., Koob, G. F., Croyle, R. T., Bianchi, D. W., Gordon, J. A., Koroshetz, W. J., Pérez-Stable, E. J., Riley, W. T., Bloch, M. H., Conway, K., et al. (2018) · Developmental Cognitive Neuroscience · doi:10.1016/j.dcn.2017.10.002 · Cited by 970 · cited 1×
“predictors of substance use disorders, particularly within adolescents and young adults.(88)”
BackgroundSelf-citationJonas, D. E., Amick, H. R., Feltner, C., Bobashev, G., Thomas, K., Wines, R., Kim, M. M., Shanahan, E., Gass, C. E., Rowe, C. J., et al. (2014) · JAMA · doi:10.1001/jama.2014.3628 · Cited by 923 · cited 1×
“findings are noted despite several rigorous meta-analyses showing effect sizes for naltrexone and acamprosate equivalent to that of selective serotonin reuptake inhibitors for depression.(15,16) As with”
ResultNational Patterns in Antidepressant Medication Treatment
Olfson, M., & Marcus, S. C. (2009) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2009.81 · Cited by 730
Magill, M., & Ray, L. A. (2009) · Journal of Studies on Alcohol and Drugs · doi:10.15288/jsad.2009.70.516 · Cited by 694 · cited 1×
“Cognitive behavioral therapy (CBT) is arguably a first-line behavioral treatment for AUD, with consistent support for the treatment of substance use disorder more broadly.(17) Despite its docu-”
BackgroundSelf-citationClark, L. A., Cuthbert, B., Lewis-Fernández, R., Narrow, W. E., & Reed, G. M. (2017) · Psychological Science in the Public Interest · doi:10.1177/1529100617727266 · Cited by 688 · cited 1×
“Without revisiting the long debate about what constitutes AUD, the study of mental disorders has moved towards a cross-diagnostic approach that focuses on specific domains that can help explain illness as a result of varying degrees of dysfunction in psychology/biological systems.(59,60)”
BackgroundDiagnosis and Pharmacotherapy of Alcohol Use Disorder: A Review
Kranzler, H. R., & Soyka, M. (2018) · JAMA · doi:10.1001/jama.2018.11406 · Cited by 580 · cited 1×
“In fact, it is estimated that medications for AUD are prescribed to only 9% of patients who need AUD treatment.(14) These”
BackgroundNielsen, L., Riddle, M., King, J. W., Aklin, W. M., Chen, W., Clark, D., Collier, E., Czajkowski, S., Esposito, L., Ferrer, R., et al. (2018) · Behaviour Research and Therapy · doi:10.1016/j.brat.2017.07.002 · Cited by 446 · cited 2×
“The Science of Behavior Change proposed intervention pipeline3 highlights the identification of intervention targets, the development of appropriate assays, and the optimization of trial designs to measure target engagement (Nielsen et al., 2018).”
MethodAddictions neuroclinical assessment: a neuroscience-based framework for addictive disorders
Kwako, L. E., Momenan, R., Litten, R. Z., Koob, G. F., & Goldman, D. (2016) · Biological Psychiatry · doi:10.1016/j.biopsych.2015.10.024 · Cited by 395
Self-citationReus, V. I., Fochtmann, L. J., Bukstein, O., Eyler, A. E., Hilty, D. M., Horvitz-Lennon, M., Mahoney, J., Pasic, J., Weaver, M., Wills, C. D., et al. (2018) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2017.1750101 · Cited by 372
Volitional social interaction prevents drug addiction in rat models
Venniro, M., Zhang, M., Caprioli, D., Hoots, J. K., Golden, S. A., Heins, C., Morales, M., Epstein, D. H., & Shaham, Y. (2018) · Nature Neuroscience · doi:10.1038/s41593-018-0246-6 · Cited by 342
Heterogeneity of Alcohol Use Disorder: Understanding Mechanisms to Advance Personalized Treatment
Litten, R. Z., Ryan, M. L., Falk, D. E., Reilly, M., Fertig, J. B., & Koob, G. F. (2015) · Alcoholism: Clinical and Experimental Research · doi:10.1111/acer.12669 · Cited by 330 · cited 2×
“AUD itself is heterogeneous, with every patient developing an AUD through an interaction of underlying neurobiological and environmental mechanisms.(22) The field of addiction too has taken on the challenge of describing its phenomenology through several domains of functioning, such as negative emotionality, executive…”
BackgroundSelf-citationA molecular mechanism for choosing alcohol over an alternative reward
Augier, E., Barbier, E., Dulman, R. S., Licheri, V., Augier, G., Domi, E., Barchiesi, R., Farris, S., Nätt, D., Mayfield, R. D., et al. (2018) · Science · doi:10.1126/science.aao1157 · Cited by 241
Self-citationInfluence of stress associated with chronic alcohol exposure on drinking
Becker, H. C. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.04.028 · Cited by 191
Self-citationDevelopment of pharmacotherapies for drug addiction: a Rosetta stone approach
Koob, G. F., Kenneth Lloyd, G., & Mason, B. J. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2828 · Cited by 154
Self-citationProbability and predictors of treatment-seeking for substance use disorders in the U.S
Blanco, C., Iza, M., Rodríguez-Fernández, J. M., Baca-García, E., Wang, S., & Olfson, M. (2015) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2015.01.031 · Cited by 146
Biomarkers in Substance Use Disorders
Volkow, N. D., Koob, G., & Baler, R. (2015) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.5b00067 · Cited by 141 · cited 1×
“translation and reverse translation of therapeutic discoveries.(7,72,73)”
Self-citationBell, R. L., Lopez, M. F., Cui, C., Egli, M., Johnson, K. W., Franklin, K. M., & Becker, H. C. (2015) · Addiction Biology · doi:10.1111/adb.12106 · Cited by 138 · cited 1×
“Consistent with an iterative model whereby preclinical and clinical findings converge to inform treatment development, recent preclinical studies have emphasized the clinical utility of compounds that affect animals mimicking the AUD phenotype.(42) Other paradigm-shifting approaches in animal modeling of AUD include t…”
MethodSelf-citationNeurofunctional domains derived from deep behavioral phenotyping in alcohol use disorder
Kwako, L. E., Schwandt, M. L., Ramchandani, V. A., Diazgranados, N., Koob, G. F., Volkow, N. D., Blanco, C., & Goldman, D. (2019) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2018.18030357 · Cited by 138 · cited 2×
“ical support through the Addictions Neuroclinical Assessment (ANA), a heuristic framework for addictive disorders, designed to create deep-phenotyping profiles coupled with factor analytic methods.(63)”
BackgroundSelf-citationKiluk, B. D., Nich, C., Buck, M. B., Devore, K. A., Frankforter, T. L., LaPaglia, D. M., Muvvala, S. B., & Carroll, K. M. (2018) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2018.17090978 · Cited by 138
King, A. C., Hasin, D., O’Connor, S. J., McNamara, P. J., & Cao, D. (2016) · Biological Psychiatry · doi:10.1016/j.biopsych.2015.05.007 · Cited by 132
Self-citationFalk, D. E., O’Malley, S. S., Witkiewitz, K., Anton, R. F., Litten, R. Z., Slater, M., Kranzler, H. R., Mann, K. F., Hasin, D. S., Johnson, B., et al. (2019) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2018.3079 · Cited by 120 · cited 2×
“This debate extends to the clinical outcomes used to evaluate novel treatments, both pharmacological and psychosocial.(29)”
BackgroundSelf-citationAddiction Biomarkers: Dimensional Approaches to Understanding Addiction
Kwako, L. E., Bickel, W. K., & Goldman, D. (2018) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2017.12.007 · Cited by 103 · cited 2×
“The dimensional approach offered by the ANA can be used to identify novel addiction biomarkers and to refine existing ones.(67) To”
BackgroundMethodShiffman, S., & Sweeney, C. T. (2008) · Health Policy · doi:10.1016/j.healthpol.2007.08.006 · Cited by 65 · cited 1×
“that OTC NRT has been used safely and effectively with continued physician engagement, increasing access to an evidence-based treatment.(82)”
What the alcohol doctor ordered from the neuroscientist
Heilig, M., & Leggio, L. (2016) · Progress in Brain Research · doi:10.1016/bs.pbr.2015.07.023 · Cited by 25 · cited 1×
“translation and reverse translation of therapeutic discoveries.(7,72,73)”
Self-citation
Cited by
Farokhnia, M., Fede, S. J., Grodin, E. N., Browning, B. D., Crozier, M. E., Schwandt, M. L., Hodgkinson, C. A., Momenan, R., & Leggio, L. (2022) · Scientific Reports · doi:10.1038/s41598-022-17190-3 · Cited by 32
Self-citationClinical neuroscience of addiction: what clinical psychologists need to know and why
Ray, L. A., & Grodin, E. N. (2021) · Annual Review of Clinical Psychology · doi:10.1146/annurev-clinpsy-081219-114309 · Cited by 18
Self-citationTime for a paradigm shift: the adolescent brain in addiction treatment
Mackiewicz Seghete, K. L., Filbey, F. M., Hudson, K. A., Hyun, B., & Feldstein Ewing, S. W. (2022) · NeuroImage: Clinical · doi:10.1016/j.nicl.2022.102960 · Cited by 8
“research both overall in the translational sphere (Ray et al., 2021), and among adolescents specifically (Silvers et al.”
BackgroundGichane, M. W., Camlin, C. S., Getahun, M., Emenyonu, N., Woolf-King, S., Sanyu, N., Katusiime, A., Fatch, R., Muyindike, W., & Hahn, J. A. (2023) · Substance Use & Misuse · doi:10.1080/10826084.2023.2244066 · Cited by 1
Metadata
- Authors
- Ray, L. A., Grodin, E. N., Leggio, L., Bechtholt, A. J., Becker, H., Feldstein Ewing, S. W., Jentsch, J. D., King, A. C., Mason, B. J., O'Malley, S., MacKillop, J., Heilig, M., & Koob, G. F.
- Venue
- Addiction Biology
- Publisher
- Wiley
- Published
- 2020-04-14
- Volume
- 26
- Issue
- 2
- Pages
- e12903-e12903
- ISSN
- 1355-6215 (ISSN-L)
- 1369-1600
- OpenAlex
- W3016165001
- Cited by
- 47
- References
- 29
- FWCI
- 3.53
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.